Genesco Inc.

GCO

CIK 0000018498 · Quarterly mode · latest period FY2026 (Q4) (ending 2026-01-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q4)

Revenue
$800M
↑+7.2% +$54Mvs FY2025 (Q1)
Operating Income
$9M
↑+135.2% +$5Mvs FY2025 (Q1)
Net Income
$5M
↑+11919.0% +$5Mvs FY2025 (Q1)
Gross Profit
$367M
↑+5.0% +$17Mvs FY2025 (Q1)

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project GCO's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$135.54
Total enterprise IV
$1.44B
Diluted shares
0.01B
Terminal PV
$1.04B (72% of total)
Year-5 FCF
$123M
YearProjected FCFDiscounted PV
+1$90M$82M
+2$98M$81M
+3$105M$79M
+4$114M$78M
+5$123M$76M
Terminal$1.68B$1.04B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$62M
investment in PP&E
Stock buybacks (TTM)
$13M
share count reduction
Stock-based comp (TTM)
$12M
non-cash dilution

Balance sheet · 2026-01-31

latest filed snapshot
Total assets
$1.39B
everything owned
Total liabilities
$826M
everything owed
Stockholders' equity
$567M
shareholder claim
Net debt
$-102M
Net cash position ($102M)

Recent performance · 63 quarters

Free Cash Flow↑+58.3% +$60M
$163M

Drill down